Estrella Immunopharma Inc. (ESLA) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Estrella Immunopharma Inc. (ESLA) dropped -11.32% to $0.73, trading at 17% of its 52-week range ($0.24 – $3.15). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
EMERYVILLE, Calif., October 26, 2026--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation ARTEMIS® T-cell therapies for the trea
Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation ARTEMIS® T-cell therapies for the treatment of cancer and
Top US market movers today: CLRO gained 76.04% among gainers, while AARD fell 61.52% among losers in the session.
Gainers Bolt Biotherapeutics (NASDAQ:BOLT) shares moved upwards by 58.8% to $6.65 during Friday's regular session. The market value of their outstanding shares is at $7.9 million. Lucid Diagnostics (NASDAQ:LUCD)
Notable after-hours gainers included LUCD, AARD, RNG and RHI; decliners included SHFS, SDST and DECK after the US session close.
STAK Inc-A led US stock gainers with a 63.5% jump and POMDOCTOR LTD - ADR led losers with a 39.83% drop in the Oct. 22, 2026 session.
Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 41.9% to $0.46 during Thursday's after-market session. The company's market cap stands at $67.1 million. Aardvark Therapeutics (NASDAQ:AARD) stock
Today's US session saw top gainers rise as much as 111.0% and top losers fall as much as 36.86%, with SHFS leading gainers and AVTX leading losers.
Gainers Profusa (NASDAQ:PFSA) shares moved upwards by 35.4% to $1.15 during Thursday's regular session. Karyopharm Therapeutics (NASDAQ:KPTI) shares increased by 29.12% to $0.55. The company's market cap
Estrella Immunopharma shares climbed 17.91% after hours following an update on its EB103 cancer therapy trial and early safety results.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ESLA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ESLA. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Estrella Immunopharma Inc. (ESLA) ranks #620 by composite RQD confidence (41/100, grade D-) and #798 by equity capitalization ($31.7M). Within this direct 5-issuer industry benchmark cohort, ESLA leads on earnings valuation at N/A trailing P/E, while ESLA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GNTA currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with ESLA at 41/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ESLA
ACTIVE
Estrella Immunopharma Inc. | D- | 41/100 | — | — | -35.0% | -11.32% | $31.7M | Benchmark Subject |
| ALGS Aligos Therapeutics Inc. | E | 26/100 | — | — | -35.0% | -2.71% | $31.4M | /algs-vs-esla → |
| MGX Metagenomi Therapeutics Inc. | D- | 41/100 | — | — | -35.0% | +1.03% | $31.4M | /mgx-vs-esla → |
| GNTA Genenta Science S.p.A. | C | 62/100 | — | — | — | +2.48% | $29.9M | /gnta-vs-esla → |
| ELUT Elutia Inc. (Class A) | E | 34/100 | — | 53.7% | -35.0% | -3.13% | $36.0M | /elut-vs-esla → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Estrella Immunopharma Inc. (ESLA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$13.1M, operating cash flow of -$1.8M, and free cash flow of -$1.8M (+88.9% YoY). On the balance sheet, ESLA closed FY2025 with $3.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$13.1M | -$1.8M | -$1.8M | $3.2M | — |
| FY2024 (FY) | 2024-06-30 | $0 | -$7.3M | -$16.1M | -$16.1M | $3.1M | — |
| FY2023 (FY) | 2023-06-30 | $0 | -$11.1M | -$1.3M | -$1.3M | — | — |
As of 2026-11-01, Estrella Immunopharma Inc. (NASDAQ: ESLA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $0.73 (-11.32% 1D, market cap $31.7M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ESLA ranks #620 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ESLA carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ALGS (Aligos Therapeutics Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $31.4M) and MGX (Metagenomi Therapeutics Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $31.4M). Among the 5-stock peer group, ESLA leads on earnings multiple (N/A) while ESLA leads on capital efficiency (-35.0% ROIC).
Per ESLA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001844417), Estrella Immunopharma Inc. generated $0 in revenue, -$13.1M in net income, and -$1.8M in free cash flow against $3.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ESLA last traded at $0.73 (-11.32% on volume of 271,206 shares), positioning the stock +25.86% above its 50-day simple moving average ($0.58) and -26.26% below its 200-day simple moving average ($0.99). Across its 52-week range of $0.24 to $3.15, ESLA sits at the 16.8% percentile with a 14-day RSI of 51.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.82).
Why ESLA Stock dropped -11.32% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.